Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:CELU NASDAQ:SGMT NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$2.90+2.8%$3.31$2.45▼$4.02$230.14M0.22268,218 shs720,563 shsCELUCelularity$2.13+4.4%$2.89$1.00▼$5.22$56.85M0.75171,031 shs92,256 shsSGMTSagimet Biosciences$7.29+1.8%$7.62$1.73▼$11.41$237.09M3.23484,573 shs318,278 shsVORVor Biopharma$37.46+2.1%$38.88$2.62▼$65.80$256.75M2.07389,991 shs390,504 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals0.00%-1.02%-12.91%-20.98%-13.95%CELUCelularity0.00%-5.33%-9.75%+3.90%-20.52%SGMTSagimet Biosciences0.00%-0.68%+0.55%-10.50%+114.41%VORVor Biopharma0.00%+11.42%-2.95%-0.64%+184.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$2.90+2.8%$3.31$2.45▼$4.02$230.14M0.22268,218 shs720,563 shsCELUCelularity$2.13+4.4%$2.89$1.00▼$5.22$56.85M0.75171,031 shs92,256 shsSGMTSagimet Biosciences$7.29+1.8%$7.62$1.73▼$11.41$237.09M3.23484,573 shs318,278 shsVORVor Biopharma$37.46+2.1%$38.88$2.62▼$65.80$256.75M2.07389,991 shs390,504 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals0.00%-1.02%-12.91%-20.98%-13.95%CELUCelularity0.00%-5.33%-9.75%+3.90%-20.52%SGMTSagimet Biosciences0.00%-0.68%+0.55%-10.50%+114.41%VORVor Biopharma0.00%+11.42%-2.95%-0.64%+184.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.00Hold$6.00106.90% UpsideCELUCelularity 2.00Hold$6.00181.69% UpsideSGMTSagimet Biosciences 2.71Moderate Buy$25.67252.08% UpsideVORVor Biopharma 2.56Moderate Buy$113.83203.88% UpsideCurrent Analyst Ratings BreakdownLatest CELU, SGMT, AVIR, and VOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/2/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.009/27/2025AVIRAtea PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CELUCelularityWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SGMTSagimet BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025VORVor BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$55.009/9/2025CELUCelularityWBB SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$6.008/18/2025CELUCelularityWBB SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageModerate Buy$6.008/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.008/11/2025SGMTSagimet BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$28.008/7/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$29.007/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ACELUCelularity$54.22M1.05N/AN/A$0.37 per share5.76SGMTSagimet Biosciences$2M118.54N/AN/A$5.08 per share1.44VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)CELUCelularity-$57.89M-$3.18N/A∞N/A-165.22%-459.57%-57.71%11/5/2025 (Estimated)SGMTSagimet Biosciences-$45.57M-$1.83N/AN/AN/AN/A-39.88%-38.40%11/13/2025 (Estimated)VORVor BiopharmaN/A-$273.20N/AN/AN/AN/AN/AN/AN/ALatest CELU, SGMT, AVIR, and VOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q1 2025CELUCelularityN/A-$1.02N/A-$1.02N/A$5.74 million8/13/2025Q2 2025SGMTSagimet Biosciences-$0.52-$0.32+$0.20-$0.32N/AN/A8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.1719.17CELUCelularityN/A0.250.19SGMTSagimet BiosciencesN/A17.5517.55VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CELUCelularity19.02%SGMTSagimet Biosciences87.86%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%CELUCelularity22.10%SGMTSagimet Biosciences14.70%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableCELUCelularity22026.69 million20.79 millionOptionableSGMTSagimet Biosciences832.52 million27.74 millionOptionableVORVor Biopharma1406.85 million65.45 millionNot OptionableCELU, SGMT, AVIR, and VOR HeadlinesRecent News About These CompaniesVor Biopharma (NYSE:VOR) Major Shareholder Sells $54,866.00 in StockOctober 4 at 6:34 AM | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 1,400 SharesOctober 3 at 12:22 AM | marketbeat.comReprogrammed Interchange Llc Sells 7,901 Shares of Vor Biopharma (NYSE:VOR) StockOctober 3 at 12:22 AM | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 32,451 SharesOctober 3 at 12:22 AM | marketbeat.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3 at 4:01 PM | globenewswire.comVor Biopharma Inc. $VOR Shares Acquired by Goldman Sachs Group Inc.October 1, 2025 | marketbeat.comVor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025September 29, 2025 | globenewswire.comVor Biopharma (NYSE:VOR) Raised to "Buy" at Stifel NicolausSeptember 26, 2025 | americanbankingnews.comVor Biopharma (NYSE:VOR) and Prime Medicine (NASDAQ:PRME) Critical SurveySeptember 26, 2025 | americanbankingnews.comVor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease PromiseSeptember 25, 2025 | seekingalpha.comVor Biopharma upgraded to Buy at Stifel on telitacicept prospectsSeptember 24, 2025 | msn.comStifel Nicolaus Upgrades Vor Biopharma (NYSE:VOR) to BuySeptember 24, 2025 | marketbeat.comVor Biopharma Shares Rise After Appointment of Navid Khan as Medical Affairs ChiefSeptember 23, 2025 | marketwatch.comVor Bio Appoints Navid Z. Khan, Ph.D.September 23, 2025 | globenewswire.comReprogrammed Interchange Llc Sells 447,278 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Stock Price Down 8.6% After Insider SellingSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 447,278 SharesSeptember 19, 2025 | marketbeat.comVor Biopharma trading halted, news pendingSeptember 19, 2025 | msn.comVor Biopharma trading halted on Thursday, news pendingSeptember 19, 2025 | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comResults of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual MeetingSeptember 17, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, SGMT, AVIR, and VOR Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$2.90 +0.08 (+2.84%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.87 -0.03 (-1.03%) As of 10/3/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Celularity NASDAQ:CELU$2.13 +0.09 (+4.41%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$2.12 -0.01 (-0.70%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Sagimet Biosciences NASDAQ:SGMT$7.29 +0.13 (+1.82%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$7.20 -0.09 (-1.23%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Vor Biopharma NYSE:VOR$37.46 +0.78 (+2.13%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$38.47 +1.01 (+2.68%) As of 10/3/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
